OKYO Pharma Ltd - Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed this Form 6-K on July 10, 2024. The filing serves to announce the issuance of a new investor presentation dated July 10, 2024, which is attached as Exhibit 99.1.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing to distribute an investor presentation and does not contain audited financial statements or specific financial data points within the text provided.
Material Changes
No material changes to financial performance or operations are detailed in the filing text. The document solely references the distribution of the attached investor presentation.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, or contingencies. It explicitly states that the information in the attached Exhibit 99.1 is furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference except as expressly set forth.
Key Facts for Investor Verification
- Verify the contents of the attached Investor Presentation (Exhibit 99.1) for actual financial data and strategic updates.
- Note that the information in the exhibit is not legally "filed" under Section 18 of the Securities Exchange Act of 1934.
- Confirm the company's status as a registrant filing under Form 20-F.
- Identify Keeren Shah as the Chief Financial Officer who authorized the report.